Printer Friendly
The Free Library
14,550,678 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Kobayashi Pharmaceutical Announces Results for the Third Quarter Ended December 31, 2006.


Tokyo, Japan, Jan 23, 2007 - (JCN JCN Japan Corporate News
JCN Journal of Cognitive Neuroscience
JCN Journal of Cardiovascular Nursing
JCN Journal of Christian Nursing
JCN Job Control Number
JCN Journal of Child Neurology
JCN joint communications network (US DoD) 
 Newswire) - Kobayashi Pharmaceutical, Ltd. (TSE See Tokyo Stock Exchange.

TSE

1. See Tokyo Stock Exchange (TSE).

2. See Toronto Stock Exchange (TSE).
: 4967), a leading importer and distributor of medical equipment and pharmaceutical and consumer goods consumer goods

Any tangible commodity purchased by households to satisfy their wants and needs. Consumer goods may be durable or nondurable. Durable goods (e.g., autos, furniture, and appliances) have a significant life span, often defined as three years or more, and
 wholesaler, today announced consolidated financial results for the third quarter ended December 31, 2006. Net sales Net Sales

The amount a seller receives from the buyer after costs associated with the sale are deducted.

Notes:
This amount is calculated by subtracting the following items from gross sales: merchandise returned for credit, allowances for damaged or missing goods, freight
 and operating, ordinary and net income all demonstrated strong improvement on the previous year.

Net sales amounted to 202,442 million yen, an increase of 5.3% from the previous fiscal year, while operating income Operating Income

The profit realized from a business' own operations.

Notes:
This would not include income from things such as investments in other firms. Also referred to as operating profit or recurring profit.
 was 16,031 million yen, an increase of 12.5%. Ordinary income was 14,076 million yen, an increase of 6.4%, and net income for the quarter was 8,470 million yen, an increase of 22.1%. The sharp increase in third-quarter net income is attributable to the 1,632 million yen impairment Impairment

1. A reduction in a company's stated capital.

2. The total capital that is less than the par value of the company's capital stock.

Notes:
1. This is usually reduced because of poorly estimated losses or gains.

2.
 charge posted a year earlier.

Despite the unstable trend in oil prices, the Japanese economy remained on a recovery track during the third quarter under review thanks to improved corporate earnings and the improved employment situation. But while consumer spending Consumer demand or consumption is also known as personal consumption expenditure. It is the largest part of aggregate demand or effective demand at the macroeconomic level.  continued to rebound, the outlook for the future remained unclear.

In these circumstances, the Company Group sought to further demonstrate its dedication to the "creativity and innovation" that is its management philosophy, uncovering unmet un·met  
adj.
Not satisfied or fulfilled: unmet demands. 
 needs among its customers by providing products and services that build new markets while at the same time working to provide products and service that add new value in markets where it already has a presence.

(1) Consolidated Operating Results
------------------------------------------------------------------------
                                                     (Millions of Yen)
                                April 1 - Dec. 31,            FY 3/31,
                              2006      %      2005     %        2006
------------------------------------------------------------------------

Operating Revenues          202,442   5.3   192,315  16.6     246,852
Operating Income             16,031  12.5    14,251   8.4      16,879
Ordinary Income              14,076   6.4    13,225   9.1      15,151
Net Income                    8,470  22.1    6,939   10.8       7,474
Net Income per Share (yen)   204.98         166.96             179.17
Net Income per Share,
 diluted (yen)               204.67         166.91             179.01

------------------------------------------------------------------------


(2) Consolidated Financial Position
------------------------------------------------------------------------
                                                     (Millions of Yen)
                                   As of December 31,  As of March 31,
                                 2006            2005            2006
------------------------------------------------------------------------

Total Assets                  171,050         161,353         151,945
Shareholders' Equity           77,592          65,533          66,811
Shareholders' Equity Ratio      43.6%           40.6%           44.0%
Shareholders' Equity
 per Share (Yen)             1,803.96        1,587.87        1,617.10

------------------------------------------------------------------------


(3) Consolidated Cash Flows
------------------------------------------------------------------------
                                                     (Millions of Yen)
                                  As of December 31,   As of March 31,
                                 2006           2005            2005
------------------------------------------------------------------------

Cash Flows from
 Operating Activities           6,768          9,705          13,159
Cash Flows from
 Investing Activities          (9,821)        (4,940)         (6,414)
Cash Flows from
 Financing Activities          (4,328)          (923)         (1,419)
Cash and Cash Equivalents,
 End of term                   16,989         22,950          24,436

------------------------------------------------------------------------


Summary of Performance by Business Segment

Consumer Products Operation

In addition to the deodorizing air fresheners air freshener nambientador m

air freshener air ndésodorisant m

air freshener air n
 that are the leading product category in this segment, Nicitol 85 (a diet pill diet pill Drug slang A euphemism for an amphetamine Vox populi An agent that either ↓ appetite or ↑ basal metabolic rate–eg, amphetamines–by prescription and OTC diet aids–eg phenylpropanolamine, ephedrine, caffeine; in high doses, DPs  for breaking up and burning abdominal fat) and Shoyo (a toothpaste toothpaste,
n See dentifrice.
 product for preventing periodontal disease Periodontal Disease Definition

Periodontal diseases are a group of diseases that affect the tissues that support and anchor the teeth. Left untreated, periodontal disease results in the destruction of the gums, alveolar bone (the part of the jaws where
) also contributed greatly to increased sales. As a result, sales grew 6,832 million yen (9.1 %) from a year earlier to 81,981 million yen. While sales were growing, the Company also enforced cost-cutting measures in areas such as manufacturing costs, and as a result operating income rose 1,564 million yen (11.6%) from a year earlier to 15,006 million yen.

Wholesale Operation

The business environment for this segment was difficult due to lackluster lack·lus·ter  
adj.
Lacking brightness, luster, or vitality; dull. See Synonyms at dull.

Adj. 1. lackluster - lacking brilliance or vitality; "a dull lackluster life"; "a lusterless performance"
 sales of seasonal products at the drugstores that are its primary customers because of unseasonable un·sea·son·a·ble  
adj.
1. Not suitable to or appropriate for the season.

2. Not characteristic of the time of year: unseasonable weather.

3. Poorly timed; inopportune.
 weather and also due to a sluggish health food market. However, sales rose 6,026 million yen (4.9%) from a year earlier to 127,906 million yen thanks to its acquisition of KS Tohoku Co., Ltd. (formerly Sowa Co., Ltd.) on April 1, 2006. However, the improvement in profit margins that was the objective behind business expansion materialized more slowly than expected, and as result operating income fell 75 million yen (31.2 %) from a year earlier to 165 million yen.

Medical Devices Operation

Sales grew steadily in this segment. In Japan, the Company began marketing products that it developed itself, and it also focused its sales efforts on operating room operating room
n. Abbr. OR
A room equipped for performing surgical operations.
 products such as electronic scalpels and on orthopedic orthopedic /or·tho·pe·dic/ (-pe´dik) pertaining to the correction of deformities of the musculoskeletal system; pertaining to orthopedics.  products, a market that is expected to grow. In the U.S., the company expanded profit margins by cutting costs in indirect areas through the introduction of a new customer management system. As a result, sales grew 1,222 million yen (9.8%) from a year earlier to 13,724 million yen and operating income increased 347 million yen (120.5%) from a year earlier to 636 million yen.

Changes in Financial Position

Total assets increased 19,105 million yen from the end of the previous fiscal year. The change is mainly attributable to a 12,432 million yen increase in notes receivable and accounts receivable accounts receivable n. the amounts of money due or owed to a business or professional by customers or clients. Generally, accounts receivable refers to the total amount due and is considered in calculating the value of a business or the business' problems in paying  and a 3,135 million yen increase in inventory assets, both of which fall under current assets Current Assets

Appearing on a company's balance sheet, it represents cash, accounts receivable, inventory, marketable securities, prepaid expenses, and other assets that can be converted to cash within one year.
, as a result of the new application of consolidating accounting to a subsidiary. At the same time, under current liabilities Current Liabilities

Usually appearing on a company's balance sheet, it represents the amount owed for interest, accounts payable, short-term loans, expenses incurred but unpaid, and other debts due within one year.
, notes payable and accounts payable also increased 10,971 million yen.

Shareholders' equity Shareholders' Equity

A firms' total assets minus its total liabilities. Equivalently, it is share capital plus retained earnings minus treasury shares. Shareholders' equity is the amount by which a company is financed through common and preferred shares.
, including minority interests, increased 7,863 million yen from the end of the previous fiscal year. As a result the shareholders' equity ratio declined 0.4 point from the end of the previous fiscal year.

Cash flows from operating activities

Cash flow from operating activities amounted to 6,768 million yen. Third-quarter net income before taxes and other adjustments was 15,710 million yen, but the Company made a corporate income tax payment of 7,401 million yen.

Cash flows from investing activities

Cash flow used in investing activities totaled 9,821 million yen. The Company acquired 990 million yen in tangible fixed assets fixed assets nplactivo sg fijo

fixed assets nplimmobilisations fpl

fixed assets fix npl
 for new product development and it acquired 10,635 million yen in stock in an M&A transaction.

Cash flows from financing activities

Cash flow used in financing activities amounted to 4,398 million yen. The Company made dividend payments totaling 1,569 million yen and repaid 2,550 million yen in short-term borrowing by a subsidiary.

(4) Consolidated Projections for the FY ending March 31, 2007
------------------------------------------------------------------------
                                                     (Millions of Yen)

Net Sales                                                     260,000
Ordinary Income                                                15,000
Net Income                                                      8,200
Net Income per Share (yen)                                     198.35

------------------------------------------------------------------------


Not only was the business climate difficult due to unseasonable weather, but the progress at the Company's new investments also fell short of objectives, and as a result the Company has revised its full-year earnings guidance announced on May 15, 2006.

*The projections shown above are prepared based on information available as of the issuing date of this report, and therefore the actual results may differ from the projected figures due to various unknown factors.

About Kobayashi Pharmaceutical

Kobayashi Pharmaceutical (TSE: 4967; OTC OTC

See: Over-the-counter.


OTC

See over-the-counter market (OTC).
: KBYPF) first opened for business in 1919, and its management policy has always been to provide people and society with wonderful comfort through "Creativity and Innovation". Over the years the Company has expanded its scope, developing into a cluster of enterprises with three principal businesses: Consumer Products Operation, Wholesale Operation and Medical Devices Operation. In the fiscal year ended March 31, 2006, Kobayashi achieved increases in sales and profits for the eighth consecutive year since the introduction of consolidated accounting.

Source: Kobayashi Pharmaceutical

Contact:
Kobayashi Pharmaceutical Online
http://www.kobayashi.co.jp/english/contact/index.html?lid=1


Copyright [c] 2007 JCN Newswire. All rights reserved. A division of Japan Corporate News Network K.K.
COPYRIGHT 2007 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCN Newswires
Date:Jan 23, 2007
Words:1253
Previous Article:JVC to Exhibit K2 Technology for High Quality Sound at MIDEM 2007; Developing Licensing Business Worldwide.
Next Article:China-made Crown 1st to Receive Five Stars in Collision Safety Tests.



Related Articles
SHAFTER IS NO MATCH FOR ALEMANY : ALEMANY 87, SHAFTER 59.(SPORTS)
Kobayashi Pharmaceutical Reports Financial Results for the First Quarter Ended June 30, 2005.
Kobayashi Pharmaceutical Announces Results for the Third Quarter Ended December 31, 2005.
Kobayashi Pharmaceutical Sets up New Subsidiary in Germany.
Kobayashi Pharmaceutical Reports Financial Results for the Year Ended March 31, 2006.
Kobayashi Pharmaceutical, Aloe Pharmaceutical to Conclude Share Transfer Agreement.
Kobayashi Pharmaceutical Reports Financial Results for the First Quarter Ended June 30, 2006.
Kobayashi Pharmaceutical Reports Financial Results for the First Half Ended Sept. 30, 2006.
King Pharmaceuticals Announces Date for Release of Fourth Quarter 2006 Earnings.(Financial report)
Kobayashi Pharmaceutical Reports Financial Results for the Year Ended March 31, 2007.

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles